Uveal and Conjunctival Malignant Melanoma in Denmark, 1943–97: Incidence and Validation Study

Isager, Peter; Osterlind, A; Engholm, Gerda; Heegaard, Steffen; Lindegaard, Jens; Overgaard, Jens; Storm, Hans H.

doi:10.1080/09286580591000836

Cited by 81 publications

(73 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…26,27 Contrary to previous reports, which have shown a slight predominance of males, 28 we found no statistically significant differences in the crude or age-adjusted incidence rates between genders. Although not fully comparable, the annual incidence of ocular melanoma in Norway has been reported to be 7.0 for women and 9.0 for men, 29 which indicates that the incidence of uveal melanoma has been relatively stable over the past several decades.…”

Section: Discussioncontrasting

confidence: 99%

Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation

Krohn

Monge

Skorpen

et al. 2007

Eye

View full text Add to dashboard Cite

Purpose To study the incidence, clinical findings, and tumour characteristics of posterior uveal melanoma in Western Norway, and to report the results of a consistent treatment strategy (I-125 brachytherapy or primary enucleation) over a 13-year period. Methods The clinical records of all patients with posterior uveal melanoma referred between January 1993 and December 2005 were reviewed. Clinical data, radiation parameters, visual outcome, and mortality were analysed in a dedicated database. Results The study included 111 consecutive patients. The annual age-adjusted incidence (per million population) of posterior uveal melanoma was 8.5 for women and 8.9 for men. Fifty-six patients underwent I-125 brachytherapy, 52 were enucleated, and three received no treatment. The median follow-up time was 36 months (mean, 52 months; range, 2 months to 13 years). In the brachytherapy group, two eyes were enucleated owing to tumour recurrence and two because of neovascular glaucoma. A visual acuity of 0.1 or better, present in 87% of the patients before brachytherapy, was retained in 40% after a median follow-up of 61 months. After brachytherapy, the 5-and 10-year melanomaspecific mortality rates were 13.4 and 23.8%, respectively. The corresponding mortality rates for patients treated with primary enucleation were 49.5 and 49.5%. Conclusion After brachytherapy, many patients lost useful vision due to radiationinduced complications. The probability of retaining the eye was high and only two patients experienced recurrent tumour growth. The mortality rates compare well with published series, and the differences in tumour size explain the difference in mortality between the two treatment groups.

show abstract

Section: Discussioncontrasting

confidence: 99%

Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation

Krohn

Monge

Skorpen

et al. 2007

Eye

View full text Add to dashboard Cite

show abstract

“…1,3,21 Although some studies describe an equal incidence in men and women, 2,3 others have reported higher frequency in male patients. 2,21 Clinical picture…”

Section: Epidemiologymentioning

confidence: 99%

Conjunctival melanoma and melanocytic intra-epithelial neoplasia

Kenawy

Lake

Coupland

et al. 2012

Eye

View full text Add to dashboard Cite

show abstract

“…The incidence rate of choroidal and ciliary body melanomas has been estimated to 0.6 per 100 000 person-years [1]. These tumours are primarily handled by enucleation or radiotherapy with some treated by local resection or other modalities.…”

mentioning

confidence: 99%

Visual outcome, local tumour control, and eye preservation after¹⁰⁶Ru/Rh brachytherapy for choroidal melanoma

et al. 2006

View full text Add to dashboard Cite

Uveal and Conjunctival Malignant Melanoma in Denmark, 1943–97: Incidence and Validation Study

Cited by 81 publications

References 55 publications

Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation

Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation

Conjunctival melanoma and melanocytic intra-epithelial neoplasia

Visual outcome, local tumour control, and eye preservation after¹⁰⁶Ru/Rh brachytherapy for choroidal melanoma

Contact Info

Product

Resources

About

Uveal and Conjunctival Malignant Melanoma in Denmark, 1943–97: Incidence and Validation Study

Cited by 81 publications

References 55 publications

Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation

Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation

Conjunctival melanoma and melanocytic intra-epithelial neoplasia

Visual outcome, local tumour control, and eye preservation after106Ru/Rh brachytherapy for choroidal melanoma

Contact Info

Product

Resources

About

Visual outcome, local tumour control, and eye preservation after¹⁰⁶Ru/Rh brachytherapy for choroidal melanoma